Laforin
| epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | |
|---|---|
| Identifiers | |
| Symbol | EPM2A |
| Entrez | 7957 |
| HUGO | 3413 |
| OMIM | 607566 |
| PDB | 4RKK |
| RefSeq | NM_001018041 |
| UniProt | O95278 |
| Other data | |
| Locus | Chr. 6 q24 |
Laforin, encoded by the EPM2A gene, is a phosphatase, with a carbohydate-binding domain, which is mutated in patients with Lafora disease.[1][2] It contains a dual specificity phosphatase domain (DSP) and a carbohydrate binding module subtype 20[3] (CBM20). Its physiological substrate has yet to be identified and the molecular mechanisms in which mutated laforin causes Lafora disease is unknown, though there has been progress made in the study by Ortolano et al.[1] Laforin regulates autophagy via Mammalian target of rapamycin, which is impaired in Lafora disease.[4]
References
- 1 2 Ortolano, S; Vieitez, I; Agis-Balboa, RC; Spuch, C (28 January 2014). "Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.". Molecular brain. 7: 7. doi:10.1186/1756-6606-7-7. PMC 3917365
. PMID 24472629. - ↑ Ganesh, S; Agarwala, KL; Ueda, K; Akagi, T; Shoda, K; Usui, T; Hashikawa, T; Osada, H; Delgado-Escueta, AV; Yamakawa, K (22 September 2000). "Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.". Human Molecular Genetics. 9 (15): 2251–61. doi:10.1093/oxfordjournals.hmg.a018916. PMID 11001928.
- ↑ "CAZy - CBM".
- ↑ Aguado, C; Sarkar, S; Korolchuk, VI; Criado, O; Vernia, S; Boya, P; Sanz, P; de Córdoba, SR; Knecht, E; Rubinsztein, DC (15 July 2010). "Laforin, the most common protein mutated in Lafora disease, regulates autophagy.". Human Molecular Genetics. 19 (14): 2867–76. doi:10.1093/hmg/ddq190. PMC 2893813. PMID 20453062.
External links
This article is issued from Wikipedia - version of the 1/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.